Form 4: VYNE Therapeutics CFO Tyler Zeronda Reports Stock Disposal for Tax Obligations

Tyler Zeronda, CFO of VYNE Therapeutics Inc., reports disposing of 94 shares of common stock on April 1, 2024, to cover tax withholding requirements related to vesting restricted stock units.

Summary

• On April 1, 2024, Tyler Zeronda, the Chief Financial Officer of VYNE Therapeutics Inc., disposed of 94 shares of the company's common stock.
• The transaction was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• The shares were disposed of at a price of $3.08 per share.
• Following the transaction, Zeronda directly owns 131,743 shares of VYNE Therapeutics Inc.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to insider transactions for tax purposes, which is neither particularly positive nor negative. It's a routine event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations, which is a common occurrence when restricted stock units vest.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.

Key Dates